260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO, CA
Departure of Chief Business Officer - Hans Hull Resigns from Pliant Therapeutics
Pliant Therapeutics Completes $32.4 Million Loan Prepayment
Amendments to Articles of Incorporation or Bylaws, Shareholder votes
Earnings Release
Material disclosure
Adopts Limited Duration Stockholder Rights Agreement
Q2
Q1
Q3
FY 2023
Registration of Securities
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Additional Proxy Materials
Definitive Proxy Statement
PRER14A
PRE 14A
Statement of Changes in Beneficial Ownership